PubMed · 2010 · 22 citations · 5 references
MedicineOncologyPharmacotherapyChemotherapyClinical PharmacologyPalliative CareAntiemetic PharmacologyAntiemetic TherapyNausea AssessmentNausea ControlPalliative PharmacotherapyVomiting ManagementAcute Chemotherapy-induced NauseaAntiemetic Guideline DevelopmentAntiemetic ResponseDelayed Chemotherapy-induced NauseaGuideline-based Antiemetic CarePalliative Care AntiemeticsRescue Antiemetic TreatmentSerotonin Antagonists
Antiemetic guidelines for chemotherapy-induced nausea and vomiting (CINV) are important to provide a framework for evidence-based care. Attention and adherence to guidelines can help to close the gap between practitioner prediction and patient experience of CINV. Recent updated recommendations have provided guidance on appropriate use of standard-of-care antiemetics--aprepitant, palonosetron, and other serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor antagonists and dexamethasone. Guidelines are also important, in that their use is often tied to Medicare or other third-party payment. Limitations of guidelines include an absence of provisions for moving patients up the risk ladder for CINV when they have a poor response to recommended antiemetic treatment, as well as an absence of recommendations for treatment beyond the first cycle of antiemetic therapy. Further work is needed to improve evidence-based care in CINV, including studies focusing on delayed CINV and studies in the palliative-care setting.
5
Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics
Steven M. Grunberg, Robert Deuson, Panagiotis Mavros et al. · Cancer · 2004 · 470 citations · Full text
Nursing, Oncology, Oncology Nursing +15
Rudolph M. Navari, Lawrence H. Einhorn, Patrick J. Loehrer et al. · Supportive Care in Cancer · 2007 · 153 citations
Medicine, Oncology, Pharmacotherapy +16